Spots Global Cancer Trial Database for The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
Official Title: The Neuroprotective Effects of Dexmedetomidine During Brain Surgery
Study ID: NCT02878707
Interventions
Study Description
Brief Summary: Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In brain tumor resection craniotomy, it is proven to be effective in improving postoperative hypertension and tachycardia, mitigates postoperative nausea and vomiting and relives postoperative pain. In addition, many animal experiments show that DEX inhibits the proapoptosis in the mitochondrial in vivo and therefore avoids neuronal injury. It is also reported to be neuroprotective to isoflurane-induced neurotoxicity and to improve cerebral focal ischemic region (penumbra). However, the neuroprotective effects were never investigated clinically in patients undergoing brain tumor resection surgery.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Taiwan University Hospital, Taipei, , Taiwan
Contact Details
Name: Chun-Yu Wu, MD
Affiliation: Anesthesiology Department, National Taiwan University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
